Skip Ribbon Commands
Skip to main content

Ultimaster™ family, one of the best drug eluting stent (DES) to treat your high bleeding risk (HBR) patients¹ ² ³

​Making a meaningful impact on society by addressing the needs of over 2.9 million patients worldwide who have already been treated with an Ultimaster™ family stent.4

Featured products: Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System, Ultimaster™ Tansei™ Sirolimus Eluting Coronary Stent System, Ultimaster™ Sirolimus Eluting Coronary Stent System

13/12/2024 -  

1. ​Do you know that ± 45% of your patients are high bleeding risk? 5​


The above​​ percentages are derived from the ARC-HBR (Academic Research Consortium for HBR), PRECISE-DAPT (Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy), and J-HBR (Japanese HBR) scores.​​​​ LM: Left Main​


​

2. Do you know how to define your HBR patient?

In interventional cardiology, an HBR patient refers to someone who has a significantly increased risk of bleeding complications, particularly when undergoing procedures like percutaneous coronary intervention (PCI).​​

Did you know that nearly 70% of your HBR patients meet at least one of the following ARC-HBR criteria?5


 

Identifying HBR patients is essential to tailor therapy, minimize bleeding risks, and choose appropriate stent types that might reduce the need for prolonged antiplatelet therapy.



3. Do you know that the Ultimaster™ family is one of the best DES to treat your HBR patients, based on MASTER DAPT study?

MASTER DAPT, the only study nowadays to define optimal duration of DAPT in HBR patients with sufficient power.1

​​

MASTER DAPT


Design Paper​

 
Learn more

Total Population

 
Learn more

OAC Patients

 
Learn more

Non-adherence

 
Learn more

Gender

 
Learn more

15-month results

 
Learn more

MI patients

 
Learn more

Complex patients

 
Learn more

Screening Log

 
Learn more

Geography

 
Learn more

Precise HBR

 
Learn more

Diabetes

 
Learn more
​ ​

What is addressed in the latest ESC guidelines?

A pivotal study that contributed to the European society of cardiology (ESC) guidelines, improving treatment options for acute and chronic HBR patients : 2,3​​​​​





4. Do you know that we continue to generate data with HBR patients​? ​

One of the priority subgroups of the NAGOMI COMPLEX study is HBR patients, who represent approximately 45% of patients recruited to date.




References

  1. Valgimigli et al. N Engl J Med 2021;385:1643-55. DOI: 10.1056/NEJMoa2108749
  2. Byrne et al. Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191.
  3. Vrintz et al. EuropeanHeartJournal, Volume 45, Issue 36, 21 September 2024, Pages 3415–3537, https://doi.org/10.1093/eurheartj/ehae177
  4. Data on file at Terumo – 2,9 million patient. Number is based on data of Ultimaster family DES sales since April 2024.
  5. Ueki et al. EuroIntervention. 2020 Aug28;16(5):371-379. doi: 10.4244/EIJ-D-20-00052.
  6. NAGOMI COMPLEXstudy.Resultspresentedat EuroPCR 2024 and EBC 2024.
  7. CaoDet al. Am Heart J Plus. 2022 Nov 9;24:100227. doi: 10.1016/j.ahjo.2022.100227
  8. Nakamura Met al. EuroIntervention. 2021 Feb 19;16(14):1154–1162. doi: 10.4244/EIJ-D-20-00345
  9. Miura K et al. Circ J. 2020 Aug25;84(9):1560-1567. doi: 10.1253/circj.CJ-20-0395. Epub 2020 Jul 16.
  10. Fujii T et al. Circ J. 2021 Jan 25;85(2):159-165. doi: 10.1253/circj.CJ-20-0806.
  11. Chiariato et al. J Am Coll Cardiol Intv. 2021 Nov, 14 (22) 2447–2457​​